CD274 and non-small cell lung carcinoma: In 2021, the US Food and Drug Administration reported a pooled analysis of anti–PD–(L)1 plus chemotherapy vs. anti–PD–(L)1 alone as 1st–line treatment for advanced NSCLC with PD–L1 TPS 1–49% (67).